This Is MS Multiple Sclerosis Community: Knowledge & Support

Its gross, no doubt, but the science behind "poop transplants" is starting to turn heads in the medical community. For MS it really speaks to the idea that gut bacteria makes a big difference in disease progression.

"...Whilst using FMT (fecal microbiota transplantation) to treat ulcerative colitis or constipation-predominant IBS in the Sydney clinic, serendipitous improvements in extraintestinal conditions not previously considered to be microbiota-related have also been observed. These include the virtually complete and ...

THE DRUG BENZTROPINE WAS TRAIL FOR TREATING M.S DETAILS PLEASE READ THE WEB SITE
http://www.medicaldaily.com/parkinsons- ... ent-259364
regards
seeva :roll:

Has anybody tried Rosiglitazone (diabetes drug) for the treatment of nerve pain? It blocks the PPAR-gamma. Whatever that means.

Hi,

I had botox in the bladder 5 monthsago but it is wearing off now
so i am going to take a medicine until my next botox, which should be January/February

Before i used to take 1x 60mg TROSPIUM before bed, but my nurse said there another drug i might want to try called Betmiga 50mg once daily.

Has anyone tried Myrbetriq / Betmiga 50mg once daily?

if so, how do you find it? how ...

MEDICAL MAFIA/CPS & CORRUPT JUSTICE SYSTEM RE: UTAH BOY WHO HAD NO CANCER:
http://vaccineliberationarmy.com/2013/1 ... no-cancer/
Regards
Rici

GALECTINS IN ARGENTINA ONE CLOSE STEP FORWARD TO REMYELINATION


Galectin-3 controls the response of microglial cells to limit
cuprizone-induced demyelination.


Hoyos HC, Rinaldi M, Mendez-Huergo SP, Marder M, Rabinovich GA, Pasquini JM, Pasquini LA.

Source
Department of Biological Chemistry, School of Pharmacy and Biochemistry, University of Buenos Aires and National Research Council (CONICET), Argentina; Institute of Chemistry and Biological Physicochemistry (IQUIFIB), School of Pharmacy and Biochemistry, University of Buenos Aires and National Research Council ...

Genmab A/S announced top-line results from a Phase II study of the subcutaneous formulation of
ofatumumab in relapsing-remitting multiple sclerosis (RRMS).

A total of 232 subjects with RRMS were randomized in the study. There was a
clear separation from placebo on the cumulative number of new gadolinium
enhancing lesions (active brain lesions) over a period of 12 weeks in subjects
treated with all doses of ofatumumab compared to subjects treated with placebo
. ...

NEW DRUG PHASE 1 CLINICAL STUDY FOR REPAIR MYELIN DAMAGED BY PROGRASIVE M.S PLEASE SEE THE DETAILS
http://www.news-medical.net/news/201304 ... rosis.aspx
regards
seeva :twisted:

Any PP tried intrathecal methotrexate? The drug can be administered off-label and some studies showed that it could halt the progression of the disease.

Hi

http://www.foxnews.com/health/2013/07/3 ... e-disease/ Confirmation from FDA: http://www.cleveland.com/healthfit/inde ... tiple.html

Regards

Rici